Kobayashi Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Kobayashi Pharmaceutical Co., Ltd. carries a market capitalization of 2.53B, placing it among publicly traded companies globally. Its enterprise value stands at 331.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.53B |
| Enterprise Value | 331.81B |
Share Statistics
Kobayashi Pharmaceutical Co., Ltd. currently has 74.34M shares outstanding.
| Shares Outstanding | 74.34M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Kobayashi Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 46.43. The price-to-sales ratio is 4.33, and the price-to-book ratio stands at 1.90.
| PE Ratio | 46.43 |
| PS Ratio | 4.33 |
| PB Ratio | 1.90 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Kobayashi Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 21.55 and an EV/FCF ratio of 40,728.42. The EV/Sales ratio of 3.59 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 21.55 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.59 |
| EV / EBITDA | 21.55 |
| EV / EBIT | 21.55 |
| EV / FCF | 40,728.42 |
Financial Position
Kobayashi Pharmaceutical Co., Ltd. maintains a current ratio of 2.92, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.36, indicating conservative leverage, while an interest coverage ratio of 1,399.73 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.92 |
| Quick Ratio | 1.50 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | 0.05 |
| Interest Coverage | 1,399.73 |
Financial Efficiency
Kobayashi Pharmaceutical Co., Ltd. posts a return on equity of 4.14 and a return on invested capital of 5.37.
| Return on Equity (ROE) | 4.14 |
| Return on Assets (ROA) | 3.30 |
| Return on Invested Capital (ROIC) | 5.37 |
| Return on Capital Employed (ROCE) | 4.13 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.48 |
Taxes
Over the trailing twelve months, Kobayashi Pharmaceutical Co., Ltd. has paid 3.02B in income taxes, reflecting an effective tax rate of 25.94.
| Income Tax | 3.02B |
| Effective Tax Rate | 25.94 |
Stock Price Statistics
Kobayashi Pharmaceutical Co., Ltd.'s stock has declined approximately -9.03019% over the past 52 weeks. The 50-day moving average sits at 34.05, while the 200-day moving average is 34.80.
| Beta (5Y) | N/A |
| 52-Week Price Change | -9.03019% |
| 50-Day Moving Average | 34.05 |
| 200-Day Moving Average | 34.80 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kobayashi Pharmaceutical Co., Ltd. generated 92.46B in revenue and converted that into 8.63B in net income, yielding earnings per share of 116.23. EBITDA reached 15.40B, while operating income came in at 15.40B.
| Revenue | 92.46B |
| Gross Profit | 46.85B |
| Operating Income | 15.40B |
| Pretax Income | 11.66B |
| Net Income | 8.63B |
| EBITDA | 15.40B |
| EBIT | 15.40B |
| Earnings Per Share (EPS) | 116.23 |
Balance Sheet
Kobayashi Pharmaceutical Co., Ltd. holds 69.67B in cash and equivalents against 749.00M in total debt, resulting in a net debt position of -56.29B. Total book value stands at 210.47B, with working capital of 89.47B providing operational flexibility.
| Cash & Cash Equivalents | 69.67B |
| Total Debt | 749.00M |
| Net Debt | -56.29B |
| Equity (Book Value) | 210.47B |
| Book Value Per Share | 2,833.08 |
| Working Capital | 89.47B |
Margins
Kobayashi Pharmaceutical Co., Ltd. operates with a gross margin of 50.66, reflecting its pricing power and cost economics. The operating margin of 16.65 and net profit margin of 9.33 provide insight into operational efficiency.
| Gross Margin | 50.66 |
| Operating Margin | 16.65 |
| Pretax Margin | 12.61 |
| Profit Margin | 9.33 |
| EBITDA Margin | 16.65 |
Stock Splits
Kobayashi Pharmaceutical Co., Ltd.'s most recent stock split took place on January 26, 2017 with a 1:2 split ratio.
| Last Split Date | 1/26/2017 |
| Split Ratio | 1:2 |
Scores
Kobayashi Pharmaceutical Co., Ltd. posts an Altman Z-Score of 6.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.81 |